Trials / Completed
CompletedNCT06637072
A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- argenx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Efgartigimod PH20 SC | Subcutaneous injection of efgartigimod PH20 SC |
Timeline
- Start date
- 2024-12-10
- Primary completion
- 2026-02-19
- Completion
- 2026-02-19
- First posted
- 2024-10-15
- Last updated
- 2026-04-06
Locations
13 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06637072. Inclusion in this directory is not an endorsement.